MX341317B - Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas. - Google Patents

Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.

Info

Publication number
MX341317B
MX341317B MX2013000540A MX2013000540A MX341317B MX 341317 B MX341317 B MX 341317B MX 2013000540 A MX2013000540 A MX 2013000540A MX 2013000540 A MX2013000540 A MX 2013000540A MX 341317 B MX341317 B MX 341317B
Authority
MX
Mexico
Prior art keywords
elastase proteins
methods
recombinant
manufacturing
proteins
Prior art date
Application number
MX2013000540A
Other languages
English (en)
Inventor
Nicholas Franano F
Bland Kimberly
D Wong Marco
C Ding Bee
Original Assignee
Proteon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics Inc filed Critical Proteon Therapeutics Inc
Publication of MX341317B publication Critical patent/MX341317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6448—Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21036—Pancreatic elastase (3.4.21.36)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos para la fabricación, purificación, formulación y uso de proteínas elastasa recombinantes, biológicamente activas. Se describen métodos recombinantes para producir proteínas elastasa terapéuticamente útiles, así como composiciones farmacéuticas que comprenden dichas proteínas elastasa. También se describen preparaciones de proteínas elastasa recombinantes novedosas y de proteína. Se describen métodos para tratar y prevenir enfermedades de los conductos biológicos utilizando las composiciones farmacéuticas que contienen las proteínas elastasa de la invención.
MX2013000540A 2007-12-04 2008-12-04 Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas. MX341317B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99231907P 2007-12-04 2007-12-04
US12/327,809 US8501449B2 (en) 2007-12-04 2008-12-03 Recombinant elastase proteins and methods of manufacturing and use thereof
PCT/US2008/085559 WO2009079220A2 (en) 2007-12-04 2008-12-04 Recombinant elastase proteins and methods of manufacturing and use thereof

Publications (1)

Publication Number Publication Date
MX341317B true MX341317B (es) 2016-08-15

Family

ID=40344763

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013000540A MX341317B (es) 2007-12-04 2008-12-04 Proteinas de elastasa recombinantes y metodos de fabricacion y uso de las mismas.
MX2010006211A MX2010006211A (es) 2007-12-04 2008-12-04 Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010006211A MX2010006211A (es) 2007-12-04 2008-12-04 Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.

Country Status (26)

Country Link
US (14) US8501449B2 (es)
EP (3) EP3176262A1 (es)
JP (3) JP5829808B2 (es)
KR (3) KR101732190B1 (es)
CN (4) CN101918547B (es)
AR (1) AR069584A1 (es)
AU (1) AU2008338743B2 (es)
BR (1) BRPI0819977A2 (es)
CA (1) CA2707051C (es)
CY (2) CY1114724T1 (es)
DK (2) DK2229440T3 (es)
ES (2) ES2436783T3 (es)
HK (1) HK1148772A1 (es)
HR (2) HRP20131135T1 (es)
HU (1) HUE032739T2 (es)
IL (2) IL206157A (es)
LT (1) LT2666854T (es)
MX (2) MX341317B (es)
NZ (2) NZ585866A (es)
PL (2) PL2229440T3 (es)
PT (2) PT2229440E (es)
RS (2) RS55982B1 (es)
RU (1) RU2611200C2 (es)
SI (2) SI2229440T1 (es)
TW (2) TWI577385B (es)
WO (1) WO2009079220A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
CN102250863B (zh) * 2011-04-29 2012-12-05 天津金斯坦生物科技有限公司 基因重组人中性粒细胞弹性蛋白酶及其制备方法和该弹性蛋白酶的医药用途
US10202630B2 (en) * 2013-03-15 2019-02-12 Alderbio Holdings Llc Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
TWI636136B (zh) 2013-03-15 2018-09-21 艾爾德生物製藥股份有限公司 在酵母菌及其它轉型細胞中多肽高產量表現用之溫度變動技術
WO2018165594A1 (en) * 2017-03-10 2018-09-13 Bolt Threads, Inc. Compositions and methods for producing high secreted yields of recombinant proteins
EP4065167A4 (en) * 2019-11-26 2024-03-27 Children's Hospital Medical Center INHIBITION OF CELA-1 FOR THE TREATMENT OF PULMONARY DISEASE
WO2021146233A1 (en) * 2020-01-14 2021-07-22 Basf Se Method for producing recombinant protein in yeast cells
JP2023545346A (ja) * 2020-08-18 2023-10-30 オンチレス・ファーマ・インコーポレイテッド 改変ブタ膵臓エラスターゼタンパク質
CA3184037A1 (en) * 2020-08-18 2022-02-24 Onchilles Pharma, Inc. Modified serine protease proproteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2508408A (en) 1943-10-11 1950-05-23 Sidney H Liebson Averaging indicator
US2546308A (en) 1948-12-29 1951-03-27 Kahler John Floor marking device
US5212068A (en) * 1985-04-05 1993-05-18 Sankyo Company Limited Human pancreatic elastase
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
JPH0673456B2 (ja) * 1986-04-26 1994-09-21 三共株式会社 ヒト・膵臓エラスタ−ゼ▲ｉ▼
US5162205A (en) 1986-04-26 1992-11-10 Sankyo Company, Limited Human pancreatic elastase I
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5543302A (en) 1988-05-27 1996-08-06 Solvay Enzymes, Inc. Proteases of altered stability to autolytic degradation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
EP0747485B1 (en) 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5503333A (en) 1993-06-23 1996-04-02 Laventure; David Duster extension tube system with dust collecting region and tube cleaner and method of using the same
US5811252A (en) 1994-07-07 1998-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modified proenzymes as substrates for proteolytic enzymes
US5955072A (en) 1994-07-13 1999-09-21 Sankyo Company, Limited Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
US7531325B2 (en) 1997-04-25 2009-05-12 Sembiosys Genetics Inc. Method for cleavage of fusion proteins
US20030207402A1 (en) 1997-08-22 2003-11-06 Erhard Kopetzki Autocatalytically activatable zymogenic precursors of proteases and their use
GB9817909D0 (en) 1998-08-17 1998-10-14 Zeneca Ltd DNA constructs
GB9908458D0 (en) 1999-04-13 1999-06-09 Queen Mary & Westfield College Enzyme
WO2000068363A2 (en) 1999-05-05 2000-11-16 Genentech, Inc. Elastase variants and substrates
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
AU7612100A (en) * 1999-09-24 2001-04-24 Johns Hopkins University, The Systems and methods for opening obstructed biological conduits
US7351549B2 (en) 2000-01-24 2008-04-01 Polymun Scientific Immunbiologische Forschung Gmbh Method for the manufacture of recombinant trypsin
WO2001062983A1 (en) 2000-02-24 2001-08-30 Phylos, Inc. Improved methods for generating catalytic proteins
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060189941A1 (en) 2002-01-22 2006-08-24 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
JP2007525423A (ja) 2003-02-20 2007-09-06 プロテオン セラピューティクス，インコーポレーテッド 生体導管の疾患を治療および予防するための方法
US7571008B2 (en) 2003-08-18 2009-08-04 Medtronic, Inc. System and apparatus for remote activation of implantable medical devices
US20070004658A1 (en) * 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
US20090196865A1 (en) 2004-09-22 2009-08-06 Proteon Therapeutics, Inc. Methods for the treatment and prevention of diseases of biological conduits
RU2299070C2 (ru) * 2005-02-08 2007-05-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения заболевания вен и способ ее получения
US20060193824A1 (en) 2005-02-28 2006-08-31 Rubin Bruce K Methods for the treatment of infectious and inflammatory airway diseases
CN1769424A (zh) * 2005-09-20 2006-05-10 浙江大学 一种芽孢杆菌菌株及其用途
KR20140072201A (ko) * 2006-07-05 2014-06-12 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
PT2271767T (pt) * 2008-04-03 2016-08-18 Cb Biotechnologies Inc Reação em cadeia de polimerase para captura de amplicões em multiplexo para amplificação de alvos múltiplos

Also Published As

Publication number Publication date
KR20160095184A (ko) 2016-08-10
CA2707051C (en) 2019-05-21
AU2008338743A1 (en) 2009-06-25
US9057060B2 (en) 2015-06-16
CY1114724T1 (el) 2016-10-05
JP2017104114A (ja) 2017-06-15
NZ601592A (en) 2014-02-28
US20190062718A1 (en) 2019-02-28
ES2627066T3 (es) 2017-07-26
ES2436783T3 (es) 2014-01-07
US20110081705A1 (en) 2011-04-07
US20090162343A1 (en) 2009-06-25
US20150329846A1 (en) 2015-11-19
US20180273928A1 (en) 2018-09-27
US20130336956A1 (en) 2013-12-19
CN109893647A (zh) 2019-06-18
KR20100120639A (ko) 2010-11-16
US20110008315A1 (en) 2011-01-13
MX2010006211A (es) 2010-10-25
US20150166974A1 (en) 2015-06-18
US20160243205A1 (en) 2016-08-25
EP2229440B9 (en) 2013-11-13
PL2666854T3 (pl) 2017-08-31
US10308924B2 (en) 2019-06-04
US20190010476A1 (en) 2019-01-10
CN101918547B (zh) 2015-01-14
HRP20131135T1 (hr) 2014-01-03
DK2229440T3 (da) 2013-12-09
WO2009079220A3 (en) 2009-08-06
US8501449B2 (en) 2013-08-06
SI2666854T1 (sl) 2017-06-30
TWI619726B (zh) 2018-04-01
AU2008338743B2 (en) 2015-02-19
IL226771A0 (en) 2013-07-31
CN104711243A (zh) 2015-06-17
EP2229440A2 (en) 2010-09-22
NZ585866A (en) 2012-09-28
RU2010127232A (ru) 2012-01-10
EP2229440B1 (en) 2013-08-28
AR069584A1 (es) 2010-02-03
DK2666854T3 (da) 2017-05-22
KR101824350B1 (ko) 2018-01-31
HRP20170755T1 (hr) 2017-07-28
US20180208918A1 (en) 2018-07-26
CN104711243B (zh) 2019-06-11
SI2229440T1 (sl) 2013-12-31
CN101918547A (zh) 2010-12-15
TW200938219A (en) 2009-09-16
EP2666854A1 (en) 2013-11-27
CN103952388B (zh) 2017-10-03
LT2666854T (lt) 2017-06-12
RS55982B1 (sr) 2017-09-29
CN103952388A (zh) 2014-07-30
IL206157A0 (en) 2010-12-30
CY1118930T1 (el) 2018-01-10
RU2611200C2 (ru) 2017-02-21
TW201643188A (zh) 2016-12-16
JP2011505164A (ja) 2011-02-24
US20150322420A9 (en) 2015-11-12
US10301612B2 (en) 2019-05-28
PL2229440T3 (pl) 2014-07-31
TWI577385B (zh) 2017-04-11
US20180155703A1 (en) 2018-06-07
PT2666854T (pt) 2017-06-28
US20200208132A1 (en) 2020-07-02
US20160319267A1 (en) 2016-11-03
PT2229440E (pt) 2013-11-11
EP2666854B1 (en) 2017-03-15
IL206157A (en) 2013-07-31
KR101732190B1 (ko) 2017-05-04
JP6084653B2 (ja) 2017-02-22
WO2009079220A2 (en) 2009-06-25
CA2707051A1 (en) 2009-06-25
HK1148772A1 (en) 2011-09-16
HUE032739T2 (en) 2017-10-30
RS53083B (en) 2014-06-30
JP5829808B2 (ja) 2015-12-09
BRPI0819977A2 (pt) 2020-08-18
EP3176262A1 (en) 2017-06-07
JP2015172056A (ja) 2015-10-01
KR20180011860A (ko) 2018-02-02

Similar Documents

Publication Publication Date Title
MX2010006211A (es) Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20055209D0 (no) Peptabody for cancerbehandling
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
TNSN07238A1 (en) Method for producing sterile suspensions or lyophilisates of poorly soluble basic peptide complexes. pharmaceutical formulations containing the same, and use thereof as medicaments
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
TW200637614A (en) Bendamustine pharmaceutical compositions
WO2004071426A3 (en) Compounds for the treatment of viral infection
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
HK1093746A1 (en) Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
NO330984B1 (no) Aminosyre-fenoksyestere, fremgangsmate for fremstilling av slike, mellomprodukter i synteseveien, farmasoytisk preparat omfattende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
BR0211761A (pt) depsipeptìdeos e processos para preparar os mesmos
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2007134118A3 (en) Protein based composition and methods of using same
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide